WideCells Group plc (LON:WDC) has reached an “inflection” point that will see it “enter a new and significant period of growth”, the company’s founder and chief executive, João Andrade, will tell its annual meeting.
He said revenues are now being received and are set to increase from both cell storage and research, and the stem cell insurance product, launching this month, will create a third income stream.
Andrade will tell investors the business had made huge strides following its main market listing around a year ago.
WATCH: Zak Mir on Widecells
READ: The AGM presentation in full
“Since this time, we have made astronomical progress in building a revenue generative end-to-end stem cell support services company,” he will say.
“Testament to this is the recognition we received from DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets, where WideCells Group was ranked as the 21st most disruptive company globally.
“This award is a great honour and I believe gives an indication of the huge impact our business is set to make on the medical world.”